{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:42:16Z","timestamp":1792453336402,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["110-2327-B-037 -001"],"award-info":[{"award-number":["110-2327-B-037 -001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["114-3111-Y-043-001"],"award-info":[{"award-number":["114-3111-Y-043-001"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04498-6","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:45:30Z","timestamp":1784630730000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dual inhibition of tumor cells and tumor-associated neutrophils by anti-CXCR2 antibodies suppresses tumor growth and augments immunotherapy efficacy in ARID1A-deficient pancreatic cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Tzu-Lei","family":"Kuo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chung","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ko-Jiunn","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Tzong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chun","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"issue":"8","key":"4498_CR1","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","volume":"33","author":"RE Royal","year":"2010","unstructured":"Royal RE et al (2010) Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33(8):828\u2013833","journal-title":"J Immunother"},{"issue":"26","key":"4498_CR2","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366(26):2455\u20132465","journal-title":"N Engl J Med"},{"issue":"6","key":"4498_CR3","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","volume":"29","author":"CW Steele","year":"2016","unstructured":"Steele CW et al (2016) CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma. Cancer Cell 29(6):832\u2013845","journal-title":"Cancer Cell"},{"issue":"5","key":"4498_CR4","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.jcmgh.2021.07.006","volume":"12","author":"SB Kemp","year":"2021","unstructured":"Kemp SB, Pasca di Magliano M, Crawford HC (2021) Myeloid cell mediated immune suppression in pancreatic cancer. Cell Mol Gastroenterol Hepatol 12(5):1531\u20131542","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"4498_CR5","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1186\/s13046-024-03178-6","volume":"43","author":"H Luo","year":"2024","unstructured":"Luo H et al (2024) Tumor-associated neutrophils upregulate Nectin2 expression, creating the immunosuppressive microenvironment in pancreatic ductal adenocarcinoma. J Exp Clin Cancer Res 43(1):258","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"4498_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","volume":"6","author":"K Li","year":"2021","unstructured":"Li K et al (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduct Target Ther 6(1):362","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"4498_CR7","first-page":"6176","volume":"13","author":"R Sturgeon","year":"2023","unstructured":"Sturgeon R, Goel P, Singh RK (2023) Tumor-associated neutrophils in pancreatic cancer progression and metastasis. Am J Cancer Res 13(12):6176\u20136189","journal-title":"Am J Cancer Res"},{"issue":"10","key":"4498_CR8","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3748\/wjg.v18.i10.1123","volume":"18","author":"Y Chen","year":"2012","unstructured":"Chen Y et al (2012) Interleukin-8, a promising predictor for prognosis of pancreatic cancer. World J Gastroenterol 18(10):1123\u20131129","journal-title":"World J Gastroenterol"},{"key":"4498_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1025805","volume":"12","author":"W Jiang","year":"2022","unstructured":"Jiang W et al (2022) Neutrophils in pancreatic cancer: potential therapeutic targets. Front Oncol 12:1025805","journal-title":"Front Oncol"},{"issue":"7","key":"4498_CR10","doi-asserted-by":"publisher","first-page":"9405","DOI":"10.1096\/fj.201902990R","volume":"34","author":"M Awaji","year":"2020","unstructured":"Awaji M et al (2020) CXCR2 signaling promotes secretory cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. FASEB J 34(7):9405\u20139418","journal-title":"FASEB J"},{"issue":"6","key":"4498_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1136\/gutjnl-2017-313738","volume":"67","author":"TM Nywening","year":"2018","unstructured":"Nywening TM et al (2018) Targeting both tumour-associated CXCR2(+) neutrophils and CCR2(+) macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut 67(6):1112\u20131123","journal-title":"Gut"},{"issue":"12","key":"4498_CR12","doi-asserted-by":"publisher","first-page":"e20190354","DOI":"10.1084\/jem.20190354","volume":"217","author":"Y Zhang","year":"2020","unstructured":"Zhang Y et al (2020) Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med 217(12):e20190354","journal-title":"J Exp Med"},{"issue":"11","key":"4498_CR13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1158\/2326-6066.CIR-16-0188","volume":"4","author":"T Chao","year":"2016","unstructured":"Chao T, Furth EE, Vonderheide RH (2016) CXCR2-dependent accumulation of tumor-associated neutrophils regulates T-cell immunity in pancreatic ductal adenocarcinoma. Cancer Immunol Res 4(11):968\u2013982","journal-title":"Cancer Immunol Res"},{"issue":"7540","key":"4498_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518(7540):495\u2013501","journal-title":"Nature"},{"key":"4498_CR16","doi-asserted-by":"publisher","first-page":"6744","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK et al (2015) Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 6:6744","journal-title":"Nat Commun"},{"key":"4498_CR17","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.1038\/ncomms8686","volume":"6","author":"M Sausen","year":"2015","unstructured":"Sausen M et al (2015) Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun 6:7686","journal-title":"Nat Commun"},{"issue":"5","key":"4498_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41591-018-0012-z","volume":"24","author":"J Shen","year":"2018","unstructured":"Shen J et al (2018) ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med 24(5):556\u2013562","journal-title":"Nat Med"},{"issue":"14","key":"4498_CR19","doi-asserted-by":"publisher","first-page":"5295","DOI":"10.18632\/oncotarget.2092","volume":"5","author":"EP Samartzis","year":"2014","unstructured":"Samartzis EP et al (2014) Loss of ARID1A expression sensitizes cancer cells to PI3K- and AKT-inhibition. Oncotarget 5(14):5295\u20135303","journal-title":"Oncotarget"},{"issue":"7","key":"4498_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70394","volume":"15","author":"TL Kuo","year":"2025","unstructured":"Kuo TL et al (2025) Arid1a deficiency sensitises pancreatic cancer to fatty acid synthase inhibition. Clin Transl Med 15(7):e70394","journal-title":"Clin Transl Med"},{"issue":"2","key":"4498_CR21","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1124\/jpet.114.221358","volume":"353","author":"DJ Nicholls","year":"2015","unstructured":"Nicholls DJ et al (2015) Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther 353(2):340\u2013350","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"4498_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13318-014-0179-8","volume":"39","author":"BE Miller","year":"2014","unstructured":"Miller BE et al (2014) The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers. Eur J Drug Metab Pharmacokinet 39(3):173\u2013181","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"2","key":"4498_CR23","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1124\/jpet.117.240705","volume":"362","author":"J Busch-Petersen","year":"2017","unstructured":"Busch-Petersen J et al (2017) Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2. J Pharmacol Exp Ther 362(2):338\u2013346","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"4498_CR24","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/1535-7163.MCT-24-0311","volume":"24","author":"EF Giurini","year":"2025","unstructured":"Giurini EF et al (2025) Looking beyond checkpoint inhibitor monotherapy: uncovering new frontiers for pancreatic cancer immunotherapy. Mol Cancer Ther 24(1):18\u201332","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"4498_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41698-024-00681-z","volume":"8","author":"Y Ju","year":"2024","unstructured":"Ju Y et al (2024) Barriers and opportunities in pancreatic cancer immunotherapy. NPJ Precis Oncol 8(1):199","journal-title":"NPJ Precis Oncol"},{"key":"4498_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213541","author":"R Sturgeon","year":"2025","unstructured":"Sturgeon R et al (2025) Neutrophil dynamics contribute to disease progression and poor survival in pancreatic cancer. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17213541","journal-title":"Cancers (Basel)"},{"issue":"2","key":"4498_CR27","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41416-022-02028-6","volume":"128","author":"G Piro","year":"2023","unstructured":"Piro G et al (2023) CXCR1\/2 dual-inhibitor ladarixin reduces tumour burden and promotes immunotherapy response in pancreatic cancer. Br J Cancer 128(2):331\u2013341","journal-title":"Br J Cancer"},{"issue":"10","key":"4498_CR28","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1136\/gutjnl-2021-326259","volume":"71","author":"J Leslie","year":"2022","unstructured":"Leslie J et al (2022) CXCR2 inhibition enables NASH-HCC immunotherapy. Gut 71(10):2093\u20132106","journal-title":"Gut"},{"key":"4498_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030515","author":"S Safarulla","year":"2022","unstructured":"Safarulla S et al (2022) CXCR2 mediates distinct neutrophil behavior in brain metastatic breast tumor. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14030515","journal-title":"Cancers (Basel)"},{"key":"4498_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1623436","volume":"16","author":"H Chen","year":"2025","unstructured":"Chen H, Xu Z, Varner J (2025) Targeting myeloid cells to improve cancer immune therapy. Front Immunol 16:1623436","journal-title":"Front Immunol"},{"issue":"2","key":"4498_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s00262-024-03856-6","volume":"74","author":"C Ma","year":"2025","unstructured":"Ma C et al (2025) Targeting immune checkpoints on myeloid cells: current status and future directions. Cancer Immunol Immunother 74(2):40","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"4498_CR32","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/s41416-024-02715-6","volume":"131","author":"JH Rannikko","year":"2024","unstructured":"Rannikko JH, Hollmen M (2024) Clinical landscape of macrophage-reprogramming cancer immunotherapies. Br J Cancer 131(4):627\u2013640","journal-title":"Br J Cancer"},{"issue":"25","key":"4498_CR33","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1016\/j.cell.2025.10.030","volume":"188","author":"M von Locquenghien","year":"2025","unstructured":"von Locquenghien M et al (2025) Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy. Cell 188(25):7099\u20137117","journal-title":"Cell"},{"issue":"12","key":"4498_CR34","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/s41422-025-01194-5","volume":"35","author":"L Chen","year":"2025","unstructured":"Chen L et al (2025) Targeted destruction of VISTA boosts anti-tumor immunotherapy. Cell Res 35(12):987\u20131002","journal-title":"Cell Res"},{"issue":"3","key":"4498_CR35","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/HEP.0000000000001185","volume":"82","author":"DJ Zabransky","year":"2025","unstructured":"Zabransky DJ et al (2025) Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma. Hepatology 82(3):599\u2013611","journal-title":"Hepatology"},{"key":"4498_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01533-2","author":"Y Kaiser","year":"2025","unstructured":"Kaiser Y et al (2025) Targeting immunosuppressive myeloid cells via implant-mediated slow release of small molecules to prevent glioblastoma recurrence. Nat Biomed Eng. https:\/\/doi.org\/10.1038\/s41551-025-01533-2","journal-title":"Nat Biomed Eng"},{"issue":"Pt C","key":"4498_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2025.110909","volume":"196","author":"JJ Bosque","year":"2025","unstructured":"Bosque JJ et al (2025) Mathematical model of tumor-macrophage dynamics in glioma to advance myeloid-targeted therapies. Comput Biol Med 196(Pt C):110909","journal-title":"Comput Biol Med"},{"key":"4498_CR38","doi-asserted-by":"crossref","unstructured":"Bridges K et al (2024) Mapping intratumoral myeloid-T cell interactomes at single-cell resolution reveals targets for overcoming checkpoint inhibitor resistance. bioRxiv","DOI":"10.1101\/2024.10.28.620093"},{"issue":"7","key":"4498_CR39","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/d41573-021-00079-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A (2021) FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov 20(7):491\u2013495","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"4498_CR40","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/nrc1913","volume":"6","author":"K Imai","year":"2006","unstructured":"Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6(9):714\u2013727","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"4498_CR41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nrd.2017.227","volume":"17","author":"PJ Carter","year":"2018","unstructured":"Carter PJ, Lazar GA (2018) Next generation antibody drugs: pursuit of the \u2018high-hanging fruit.\u2019 Nat Rev Drug Discov 17(3):197\u2013223","journal-title":"Nat Rev Drug Discov"},{"key":"4498_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1272523","volume":"14","author":"R Li","year":"2023","unstructured":"Li R et al (2023) Editorial: novel small molecules in targeted cancer therapy. Front Pharmacol 14:1272523","journal-title":"Front Pharmacol"},{"issue":"1","key":"4498_CR43","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","volume":"6","author":"L Zhong","year":"2021","unstructured":"Zhong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther 6(1):201","journal-title":"Signal Transduct Target Ther"},{"key":"4498_CR44","unstructured":"O'Reilly EM et al (2026) Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. N Engl J Med"},{"key":"4498_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23042168","author":"J Korbecki","year":"2022","unstructured":"Korbecki J et al (2022) CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23042168","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4498_CR46","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/imr.13394","volume":"328","author":"HJ van der Horst","year":"2024","unstructured":"van der Horst HJ, Mutis T (2024) Enhancing Fc-mediated effector functions of monoclonal antibodies: the example of HexaBodies. Immunol Rev 328(1):456\u2013465","journal-title":"Immunol Rev"},{"key":"4498_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1037033","volume":"14","author":"A Cottignies-Calamarte","year":"2023","unstructured":"Cottignies-Calamarte A, Tudor D, Bomsel M (2023) Antibody Fc-chimerism and effector functions: when IgG takes advantage of IgA. Front Immunol 14:1037033","journal-title":"Front Immunol"},{"key":"4498_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.856961","volume":"13","author":"T Dunlap","year":"2022","unstructured":"Dunlap T, Cao Y (2022) Physiological considerations for modeling in vivo antibody-target interactions. Front Pharmacol 13:856961","journal-title":"Front Pharmacol"},{"issue":"2","key":"4498_CR49","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","volume":"157","author":"P Chames","year":"2009","unstructured":"Chames P et al (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157(2):220\u2013233","journal-title":"Br J Pharmacol"},{"issue":"12","key":"4498_CR50","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60(12):1421\u20131434","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"4498_CR51","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s10637-023-01410-2","volume":"42","author":"AJ Armstrong","year":"2024","unstructured":"Armstrong AJ et al (2024) CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Invest New Drugs 42(1):145\u2013159","journal-title":"Invest New Drugs"},{"key":"4498_CR52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17182963","author":"ME Kowalkowska","year":"2025","unstructured":"Kowalkowska ME et al (2025) Tumor mutational burden in cervical cancer as potential marker for immunotherapy responders. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17182963","journal-title":"Cancers (Basel)"},{"key":"4498_CR53","doi-asserted-by":"crossref","unstructured":"Mei-Ren, Pan et al (2016) The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer Oncotarget 7(38) 61136-61151","DOI":"10.18632\/oncotarget.11256"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04498-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04498-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:22:24Z","timestamp":1792452144000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04498-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4498"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04498-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have declared that no conflict of interest exists.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"250"}}